Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7044261 | 0.77 | LMNA (0.42) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL24132612 | 0.74 | ALDH1A1 (0.38) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL5605139 | 0.74 | SMN1; SMN2 (0.41) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL5605807 | 0.74 | MEN1 (0.38) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL14352949 | 0.73 | TDP1 (0.37) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL5605731 | 0.73 | ALDH1A1 (0.36) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL4416927 | 0.73 | MCL1 (0.50) | ALDH1A1KMT2ATDP1 | |
| SCHEMBL17050501 | 0.71 | PARP15 (0.40) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL1251490 | 0.70 | TSHR (0.33) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL210293 | 0.70 | MAOA (0.55) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499577-B1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-6946471-B2 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1499577-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | BRANDT MICHAEL | 2004-10-28 | — | — | US | disclosed |
| US-6790852-B2 | HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003087026-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | CYP2D6, CYP2F1, CYP1A2 | MEN1 1726/4885ALDH1A1 115/4885KMT2A 933/4885 |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | CYP2D6, CYP1A2, CYP2F1 | MEN1 1918/4885ALDH1A1 89/4885KMT2A 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.